{
    "clinical_study": {
        "@rank": "69025", 
        "arm_group": [
            {
                "arm_group_label": "Medication Monitoring & Case Management", 
                "arm_group_type": "Experimental", 
                "description": "All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training.  Participants randomized to this group will meet with the study clinicians 4 times a year for medication monitoring and adjustment. This group will also receive a monthly call from a case manager who will explore the child's academic, social and emotional functioning.  Depending on the needs of the child and family, the case manager may offer 1 to 5 intervention sessions with the child (e.g. social skills, anger management), the family (e.g. family counselling), and the school (e.g. consultation with the teacher)."
            }, 
            {
                "arm_group_label": "Community Follow-up Group", 
                "arm_group_type": "Active Comparator", 
                "description": "All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Families randomized to this group will be referred to their pediatricians or family physicians for medication follow-up and their local Community Health Clinic (CLSC) for other psychosocial interventions that may be required and available."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to examine how well two types of treatment follow up work\n      compared to one another:\n\n        1. standard community follow up\n\n        2. medication monitoring plus tailored case management follow up.\n\n      A child's participation will involve 3 months of treatment consisting of medication and\n      psychological, behavioural, and academic interventions tailored to their individual needs.\n\n      Following this treatment, the child will be randomly assigned to receive two years of either\n      community follow up or medication monitoring plus tailored case management follow up\n      delivered by the study team. During both types of follow up, at 6 month intervals, the\n      parent and child will be asked to complete interviews with our study personnel and\n      comprehensive assessments pertaining to ADHD symptoms and various other areas of\n      functioning.\n\n      Parents will also be asked to obtain information from the child's teacher regarding the\n      child's functioning at 6 month intervals during the school year."
        }, 
        "brief_title": "Follow up Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Attention Deficit Hyperactivity Disorder (ADHD)", 
        "condition_browse": {
            "mesh_term": [
                "Attention Deficit Disorder with Hyperactivity", 
                "Hyperkinesis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age 6 to 12 years\n\n          -  DSM-IV ADHD diagnosis by a specialist i.e. child psychiatrist or       developmental\n             paediatrician (DSM 5 ADHD criteria do not differ dramatically from DSM IV criteria\n             for children)\n\n          -  Intelligence Quotient (IQ) > 80 as per the Wechsler Intelligence Scale for Children\n             (WISC-IV)\n\n          -  Proficiency in English or French\n\n        Exclusion Criteria:\n\n          -  History of Autism Spectrum Disorder (ASD) or psychosis\n\n          -  Significant brain traumas (encephalitis, head injury requiring hospitalization, etc.)\n\n          -  Major medical conditions or impairments that would interfere with the ability of the\n             child to complete testing or take psychostimulants, e.g., epilepsy, cardiac\n             abnormalities, or renal abnormalities."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "12 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "326", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142140", 
            "org_study_id": "MOP 123412"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Medication Monitoring & Case Management", 
                    "Community Follow-up Group"
                ], 
                "description": "This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.", 
                "intervention_name": "Academic and Organization skills", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": [
                    "Medication Monitoring & Case Management", 
                    "Community Follow-up Group"
                ], 
                "description": "The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively.  Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses.  Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.", 
                "intervention_name": "Parent Training", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": [
                    "Medication Monitoring & Case Management", 
                    "Community Follow-up Group"
                ], 
                "description": "Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective.  The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement.  The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.", 
                "intervention_name": "Social Skills Training", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Medication Monitoring & Case Management", 
                "description": "The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring. In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.", 
                "intervention_name": "Long-acting stimulant", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Biphentin", 
                    "Strattera", 
                    "Concerta", 
                    "Ritalin", 
                    "Vyvanse", 
                    "Adderall", 
                    "Dexedrine"
                ]
            }, 
            {
                "arm_group_label": "Community Follow-up Group", 
                "description": "The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.", 
                "intervention_name": "Long-acting stimulant", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Biphentin", 
                    "Strattera", 
                    "Concerta", 
                    "Ritalin", 
                    "Vyvanse", 
                    "Adderall", 
                    "Dexedrine"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Central Nervous System Stimulants", 
                "Dextroamphetamine", 
                "Adderall", 
                "Atomoxetine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Treatment of ADHD", 
            "Long-term treatment follow-up"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "joy.etcovitch@mail.mcgill.ca", 
                    "last_name": "Joy Etcovitch, MA", 
                    "phone": "514-412-4400", 
                    "phone_ext": "23784"
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3Z 1P2"
                    }, 
                    "name": "Montreal Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Lily Hechtman, MD, FRCP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "johanne.bellingham@douglas.mcgill.ca", 
                    "last_name": "Johanne Bellingham", 
                    "phone": "514-761-6131", 
                    "phone_ext": "2098"
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H4H 1R3"
                    }, 
                    "name": "Douglas Mental Health University Institute"
                }, 
                "investigator": [
                    {
                        "last_name": "Natalie Grizenko, MD, FRCPC", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ridha Joober, MD, PhD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Careful Medication and Tailored Case Management Follow up Treatment for Children With Attention Deficit Hyperactivity Disorder", 
        "overall_contact": {
            "email": "joy.etcovitch@mail.mcgill.ca", 
            "last_name": "Joy Etcovtich, MA", 
            "phone": "514-412-4400", 
            "phone_ext": "23784"
        }, 
        "overall_contact_backup": {
            "email": "johanne.bellingham@douglas.mcgill.ca", 
            "last_name": "Johanne Bellingham", 
            "phone": "514-761-6131", 
            "phone_ext": "2098"
        }, 
        "overall_official": [
            {
                "affiliation": "McGill University Health Center", 
                "last_name": "Lily Hechtman, MD, FRCPC", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Douglas Mental Health University Institute", 
                "last_name": "Natalie Grizenko, MD, FRCPC", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Douglas Mental Health University Institute", 
                "last_name": "Ridha Joober, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Canadian Institutes of Health Research", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Attention Deficit Hyperactivity Disorder  (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version)", 
                "safety_issue": "No", 
                "time_frame": "At baseline - no medication"
            }, 
            {
                "measure": "Attention Deficit Hyperactivity Disorder  (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version)", 
                "safety_issue": "No", 
                "time_frame": "Following 3 months of tailored treatment (including medication)"
            }, 
            {
                "measure": "Attention Deficit Hyperactivity Disorder  (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version)", 
                "safety_issue": "No", 
                "time_frame": "Six months after tailored treatment ends - on medication"
            }, 
            {
                "measure": "Attention Deficit Hyperactivity Disorder  (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version)", 
                "safety_issue": "No", 
                "time_frame": "Twelve months after tailored treatment has ended - on medication"
            }, 
            {
                "measure": "Attention Deficit Hyperactivity Disorder  (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version)", 
                "safety_issue": "No", 
                "time_frame": "Eighteen months after tailored treatment has ended - on medication"
            }, 
            {
                "measure": "Attention Deficit Hyperactivity Disorder  (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version)", 
                "safety_issue": "No", 
                "time_frame": "Twenty-four months after tailored treatment has ended - on medication"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142140"
        }, 
        "responsible_party": {
            "investigator_affiliation": "McGill University Health Center", 
            "investigator_full_name": "Lily Hechtman", 
            "investigator_title": "Professor of Psychiatry and Pediatrics; Director of Research - Division of Child Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Social skills (measured via Parent and Teacher Social Skills Rating Scale)", 
                "safety_issue": "No", 
                "time_frame": "At baseline - no medication"
            }, 
            {
                "measure": "Academic achievement (measured via Wechsler Individual Achievement Test (WIAT))", 
                "safety_issue": "No", 
                "time_frame": "At baseline - no medication"
            }, 
            {
                "measure": "Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL))", 
                "safety_issue": "No", 
                "time_frame": "At baseline - no medication"
            }, 
            {
                "measure": "Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS))", 
                "safety_issue": "No", 
                "time_frame": "At baseline - no medication"
            }, 
            {
                "measure": "Overall functioning (measured via the Clinical Global Impression Scale (CGI))", 
                "safety_issue": "No", 
                "time_frame": "Assessed at baseline"
            }, 
            {
                "measure": "Social skills (measured via Parent and Teacher Social Skills Rating Scale)", 
                "safety_issue": "No", 
                "time_frame": "Following 3 months of tailored treatment (including medication)"
            }, 
            {
                "measure": "Social skills (measured via Parent and Teacher Social Skills Rating Scale)", 
                "safety_issue": "No", 
                "time_frame": "Six months after tailored treatment ends - on medication"
            }, 
            {
                "measure": "Social skills (measured via Parent and Teacher Social Skills Rating Scale)", 
                "safety_issue": "No", 
                "time_frame": "Twelve months after tailored treatment has ended - on medication"
            }, 
            {
                "measure": "Social skills (measured via Parent and Teacher Social Skills Rating Scale)", 
                "safety_issue": "No", 
                "time_frame": "Eighteen months after tailored treatment has ended - on medication"
            }, 
            {
                "measure": "Social skills (measured via Parent and Teacher Social Skills Rating Scale)", 
                "safety_issue": "No", 
                "time_frame": "Twenty-four months after tailored treatment has ended - on medication"
            }, 
            {
                "measure": "Academic achievement (measured via Wechsler Individual Achievement Test (WIAT))", 
                "safety_issue": "No", 
                "time_frame": "Twelve month after tailored treatment has ended - on medication"
            }, 
            {
                "measure": "Academic achievement (measured via Wechsler Individual Achievement Test (WIAT))", 
                "safety_issue": "No", 
                "time_frame": "Twenty-four months after tailored treatment has ended"
            }, 
            {
                "measure": "Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL))", 
                "safety_issue": "No", 
                "time_frame": "Following 3 months of tailored treatment (including medication)"
            }, 
            {
                "measure": "Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL))", 
                "safety_issue": "No", 
                "time_frame": "Six months after tailored treatment ends - on medication"
            }, 
            {
                "measure": "Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL))", 
                "safety_issue": "No", 
                "time_frame": "Twelve months after tailored treatment has ended - on medication"
            }, 
            {
                "measure": "Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL))", 
                "safety_issue": "No", 
                "time_frame": "Eighteen months after tailored treatment has ended - on medication"
            }, 
            {
                "measure": "Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL))", 
                "safety_issue": "No", 
                "time_frame": "Twenty-four months after tailored treatment has ended - on medication"
            }, 
            {
                "measure": "Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS))", 
                "safety_issue": "No", 
                "time_frame": "Following 3 months of tailored treatment (including medication)"
            }, 
            {
                "measure": "Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS))", 
                "safety_issue": "No", 
                "time_frame": "Six months after tailored treatment ends - on medication"
            }, 
            {
                "measure": "Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS))", 
                "safety_issue": "No", 
                "time_frame": "Twelve months after tailored treatment has ended - on medication"
            }, 
            {
                "measure": "Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS))", 
                "safety_issue": "No", 
                "time_frame": "Eighteen months after tailored treatment has ended - on medication"
            }, 
            {
                "measure": "Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS))", 
                "safety_issue": "No", 
                "time_frame": "Twenty-four months after tailored treatment has ended - on medication"
            }, 
            {
                "measure": "Overall functioning (measured via the Clinical Global Impression Scale (CGI))", 
                "safety_issue": "No", 
                "time_frame": "Following 3 months of tailored treatment (including medication)"
            }, 
            {
                "description": "For participants randomized to the medication monitoring and tailored case management follow-up group.", 
                "measure": "Overall functioning (measured via the Clinical Global Impression Scale (CGI))", 
                "safety_issue": "No", 
                "time_frame": "Three months after tailored treatment ends - on medication"
            }, 
            {
                "description": "For participants randomized to the medication monitoring and tailored case management follow-up group.", 
                "measure": "Overall functioning (measured via the Clinical Global Impression Scale (CGI))", 
                "safety_issue": "No", 
                "time_frame": "Six months after tailored treatment ends - on medication"
            }, 
            {
                "description": "For participants randomized to the medication monitoring and tailored case management follow-up group.", 
                "measure": "Overall functioning (measured via the Clinical Global Impression Scale (CGI))", 
                "safety_issue": "No", 
                "time_frame": "Nine months after tailored treatment ends - on medication"
            }, 
            {
                "description": "For participants randomized to the medication monitoring and tailored case management follow-up group.", 
                "measure": "Overall functioning (measured via the Clinical Global Impression Scale (CGI))", 
                "safety_issue": "No", 
                "time_frame": "Twelve months after tailored treatment ends - on medication"
            }, 
            {
                "description": "For participants randomized to the medication monitoring and tailored case management follow-up group.", 
                "measure": "Overall functioning (measured via the Clinical Global Impression Scale (CGI))", 
                "safety_issue": "No", 
                "time_frame": "Fifteen months after tailored treatment ends - on medication"
            }, 
            {
                "description": "For participants randomized to the medication monitoring and tailored case management follow-up group.", 
                "measure": "Overall functioning (measured via the Clinical Global Impression Scale (CGI))", 
                "safety_issue": "No", 
                "time_frame": "Eighteen months after tailored treatment ends - on medication"
            }, 
            {
                "description": "For participants randomized to the medication monitoring and tailored case management follow-up group.", 
                "measure": "Overall functioning (measured via the Clinical Global Impression Scale (CGI))", 
                "safety_issue": "No", 
                "time_frame": "Twenty-one months after tailored treatment ends - on medication"
            }, 
            {
                "description": "For participants randomized to the medication monitoring and tailored case management follow-up group.", 
                "measure": "Overall functioning (measured via the Clinical Global Impression Scale (CGI))", 
                "safety_issue": "No", 
                "time_frame": "Twenty-four months after tailored treatment ends - on medication"
            }
        ], 
        "source": "McGill University Health Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Canadian Institutes of Health Research  (CIHR)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "McGill University Health Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}